LOS ANGELES--(BUSINESS WIRE)--

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the October 21, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired American Renal Associates Holdings, Inc. (“American Renal” or the “Company”) (NYSE: ARA) securities: (1) pursuant and/or traceable to American Renal’s false and misleading Registration Statement and Prospectus issued in connection with the Company’s initial public offering on or around April 21, 2016 (the “IPO” or the “Offering”); and/or (2) on the open market between April 21, 2016 and August 18, 2016, both dates inclusive (the “Class Period”).

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements or failed to disclose that: (i) American Renal was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act (“ACA”) plans to obtain greater reimbursement for the Company’s dialysis services; (ii) the foregoing scheme was in violation of federal and state laws; and (iii) as a result of the foregoing, American Renal’s public statements were materially false and misleading at all relevant times.

If you purchased or otherwise acquired American Renal shares during the Class Period, you may move the Court no later than October 31, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161021005123/en/